In humans, MASLD correlates with low circulating IGF-I levels [34,35], with IL-6 and IGF-I serving as independent prognostic factors for liver steatosis and MASH in morbidly obese patients [36]. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.